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ABSTRACT
The need to find more efficient and cost-effective methods of drug development has led
pharmaceutical companies to examine combinatorial means of synthesis. The ability to
carry out parallel synthesis by the hundreds of compounds is rapidly advancing synthetic,
analytical, and biological research. In this thesis project, peptide derivatives of ethyl p-
aminobenzoate were synthesized via solution phase combinatorial techniques. A total of
27 tri-peptide analogs were produced, using a polymer-supported carbodiimide resin as
the coupling agent. The structures of all products and intermediates were confirmed by
LC-MS. Two methods were used for sequential deprotection of these analogs. The
traditional method using the mild base, piperidine, was used as well as a polymer-
supported thiophenol method. Upon comparison of both methods, we concluded that the
piperidine deprotection afforded a higher yield of the desired unprotected peptide.
IX
1 INTRODUCTION
1.1 COMBINATORIAL CHEMISTRY
The average time it takes a company to bring a drug to market is 14 years, with a
cost of $359 million . Therefore, the speed at which a compound is produced, along with
the cost of production, is critical. Thus, combinatorial chemistry has emerged as a
powerful new technology, allowing chemists to synthesize large numbers of compounds
for both drug design and biological evaluation.
Combinatorial synthesis involves the preparation of large numbers of
structurally related compounds either as mixtures in split-pool synthesis or as individual
compounds by parallel synthesis. In this manner, hundreds to millions of compounds can
be synthesized in the time usually taken to prepare a small number of analogues by the
orthodox
methodology^
.
This area of research allows for the production of diverse, yet predictable,
collections ofmolecules using the combination and optimization of a small number of
chemical reactions. In addition, the recent advances in robotics can provide fast
throughput of these compounds. The field of combinatorial chemistry seems to be
expanding in all areas, and these techniques are now utilized in the fields of natural
products, antibiotics, catalysis, and biomaterials
Although combinatorial chemistry is rapidly becoming a core technology in
several industries, it is still in its youth, and development continues . Both synthetic and
analytical chemists are constantly looking for ways to improve techniques in synthesis,
screening, characterization, validation, and automated purification of thousands of
compounds now produced in much shorter periods of time.
1 .2 HISTORY OF COMBINATORIAL CHEMISTRY
Scientifically speaking, combinatorial chemistry is a relatively new branch of
chemistry. In 1963, R.B. Merrifield investigated a new approach to the chemical
synthesis of polypeptides through the use of solid-phase techniques4. As seen in Scheme
1.1, this technique involved the stepwise addition of protected amino acids to a specific
sequence peptide chain, which was bound by a covalent bond to a solid resin particle.
This new approach in peptide synthesis was the result of technical difficulties that arose
during the synthesis of long chain polypeptides. This classic technique of solid-phase
synthesis quickly became the key to the production of entire proteins and enzymes for the
next 30 years5.
In the mid 1980's, Mario Geysen began synthesizing peptides by the hundreds,
first in parallel fashion and later as mixtures. Geysen described a procedure for the rapid
concurrent synthesis on solid supports of hundreds of peptides6. Polyethylene rods were
used as solid supports, where reactions were carried out at the tips of the rods. By this
method a whole virus epitope was examined at a resolution of a single amino acid.
Prior to combinatorial techniques, the time required for the synthesis of hundreds
of compounds was the limiting factor in production. A combinatorial approach to peptide
synthesis was first introduced by Richard Houghten in 1985 . By using a combination of
solid-phase and random combinatorial techniques, a large number of peptides were
synthesized and for the first time, synthesis was no longer the limiting factor in drug
discovery. Houghten was able to prepare and characterize 248 different 13-residue
peptides in less than 4 weeks. Houghten used polypropylene mesh packets to encase the
amino acid resin. This method, also known as the "tea bag" method of synthesis, can be
used for simultaneous multiple-peptide synthesis or for multiple analog peptide synthesis.
Scheme 1.1:Merrifield's Solid Phase Peptide Synthesis
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The next advancement in combinatorial techniques came six years later when Kit
S. Lam developed a new type of synthetic peptide library for identifying ligand-binding
activity . This library was created by pooling millions of beads, with each bead
containing a single peptide. This complete collection ofbeads then represented the
universe ofpossible random peptides. This became known as the "one bead-one
compound"
technique, where one bead was capable of creating a diverse library of
structurally similar molecules.
Considered a breakthrough year, it was 1998 when combinatorial chemistry was
extended from peptides to small molecules9. This resulted in a large increase in drug
candidates in clinical trials, and the birth of two new scientific journals devoted
exclusively to combichem . It also resulted in many small custom synthesis businesses
developed for the rapid production of libraries ofmolecular analogs. Although this area
of research has its roots in peptide chemistry, the ability to carry out parallel synthesis by
the hundreds is spawning new excitement in synthetic, analytical, and biological research.
1.3 VARIABLE METHODS
1.3.1 Parallel Synthesis
Combinatorial parallel synthesis has become firmly established within the
pharmaceutical industry as a means of rapidly producing large numbers of compounds for
biological assays in a time- and resource-effective manner .
Figure 1.1: Parallel Synthesis
A B C [) E
A AA BA CA DA EA
B AB BB CB DB EB
C AC BC CC DC EC
D AD BD CD DD ED
E AE BE CE DE EE
The main concept in the field ofparallel synthesis can be summarized in Fig. 1 .
This table illustrates a hypothetical combinatorial compound library ofproducts produced
by reacting every possible combination of five starting materials. This results in a library
containing 25 (5 x 5) products. This library is constructed by 25 individual reactions,
with each product separate from all of the others.
Each reaction takes place simultaneously, with each reaction vessel containing the
same resin. Since each reaction vessel contains only one product, isolation of the
compound is simple, and most likely will be ofhigh purity. Another key advantage to
this parallel synthesis technique is that structure activity relationships can be easily
determined. The diversity of such libraries is only restricted by the selection ofwhich
substituents are incorporated onto the template and the subset of products that is desired.
1.3.2 Solid-Phase Synthesis
Library generation may be accomplished using solid-phase organic synthesis or
by using conventional solution-phase chemistry. Solid-phase peptide synthesis, for
example, is based on sequential addition of a-amino and side-chain protected amino acid
residues to an insoluble polymeric support". A protecting group is chosen for N-a-
protection. After removal of this protecting group, the next protected amino acid is added
using either a coupling reagent or pre-activated protected amino acid derivative. The
resulting peptide is attached to the resin, and may be cleaved to yield the desired free
product.
Solid-supported synthesis has several clear advantages over conventional
solution-phase chemistry. A summary of the advantages and disadvantages can be seen
in Table 1.1.
Table 1.1: Advantages and Disadvantages of Solid-Phase Synthesis
Advantages Disadvantages
Ease ofmanipulation of the beads. Reaction-scale restriction.
Has the ability to drive reactions to
completion by the use of excess reagent.
Only a narrow range of reactions can be
used.
The isolation ofproduct by filtration alone. Difficulty of analysis and reaction tracking.
Possibility of the split pool approach.
The development ofnew reactions on a
solid-phase is frequently time consuming.
All work-up procedures can be automated.
Reactions at high temperatures may cause
the deformation ofbeads.
1.3.3 Solution-Phase Synthesis
There is an unending controversy as to which of the major synthetic strategies for
library synthesis is superior. Solution-phase combinatorial approaches have recently
become of interest as an alternative drug discovery avenue for lead discovery and
optimization. A summary of the disadvantages and advantages in solution-phase
synthesis can be seen in Table 1.2.
Table 1.2: Advantages and Disadvantages of Solution-Phase Synthesis
Advantages Disadvantages
The familiarity to the synthetic chemist.
Complicated work-up procedures have
been a major hurdle to automation.
Able to produce products of high purity
and easy scale-up.
Often slow removal of contaminants.
Any chemical reaction can be carried out
even with the use of organometallic
reagents.
Variable quality of libraries produced.
Reactions are easy to track and analyze.
Product isolation is associated with solvent
evaporation.
High temperature reactions can be carried
out with ease.
Excess reagents can not be recovered.
Both the solid support and the solution-phase synthetic techniques have
advantages over each other. A solid support offers the ease of separating the product
away from the reaction medium and easy manipulation of the beads using volumetric
techniques. The ability to drive reactions to completion by use of excess reagent is also a
key advantage to a polymer of solid-supported synthesis. However, the loading capacity
of a solid support is fairly small, and therefore this limits the scale at which a reaction can
occur.
Solution-phase synthetic techniques have the advantage ofnon-limiting scale that
can be easily manipulated as well. There are several analytical techniques available for
screening reaction mixtures in solution, therefore decreasing validation time. The main
disadvantage to this technique is the isolation ofproducts away from the reaction medium
may require tedious and costly isolation and purification methods, especially when a
mixture ofproducts is produced.
1.3.4 Solution-Phase Synthesis on a Solid Support
In the recent years, the attention of combinatorial chemistry has shifted to the
production of
"drug-like"
small molecules for lead discovery and optimization". While
both solid-phase and solution-phase synthetic techniques have been employed to generate
libraries, the majority of the compound libraries have been synthesized on a solid
support1
.
Several recently described syntheses employ both solid-phase techniques with
solution-phase synthesis
'
. In one such example, polymeric reagents were used in the
synthesis steps to generate reactive species for product formation. In addition,
scavenging resins were used in solution reactions to remove unreacted starting materials
from product mixtures affording purified product by direct filtration12. This approach
combines the advantages from both techniques, and allows the chemist to have the best of
both worlds.
1.3.5 Selection of the Polymer-Supported Resin
Covalently linked reagents to an insoluble organic polymer have come to acquire
importance since the introduction of the solid-phase technique for the synthesis of
peptides by Merrifield in 1963 .
The chosen polymer must be insoluble in all of the solvents that are to be used,
and have a stable physical form that will permit ready filtration. It also must contain a
functional group to which the first protected amino acid could be linked by a covalent
bond. This linker must be compatible with all synthetic steps, yet labile under cleavage
conditions that do not cause decomposition of compounds generated in the library.
1.3.6 Polymer-Supported Carbodiimide Reagents
The massive increase in the number of papers describing the use of polymeric
supports in organic synthesis over the past decade is a vivid demonstration of its impact
in the chemical community. Figure 1 .2 illustrates this growing number of new and novel
utilization of linkers in organic synthesis. Few other changes in synthetic chemistry
methodology have displayed such a growing passion or had such a profound influence on
the way synthetic chemistry is carried out15.
Figure 1.2: Number of Publications Dedicated to New or Novel Utilization
of linkers
140 -,
120
100
80
60
40
20 I I I I I I I I
63- 68- 73- 78- 83- 88- 93 94 95 96 97 98 mid
67 72 77 82 87 92 99
These insoluble, polymer supports have a gel-type structure that readily allows
penetration of reagents and solvents into the beads to sites where the reactions will occur.
Typical supports used for solid-phase synthesis consist ofpolystyrene with a 1-2%
divinylbenzene cross-linking.
A few other materials are used as supports, but the polystyrene resin still
dominates today. Among other materials used are Tenta Gel resins (TG) and ArgoGel
(AG), specifically used when polar solvents are needed or when distancing from the resin
core becomes necessary. Both resins consist of polystyrene/DVB-poly(ethylene glycol)
and are graft copolymers. Crowns/Pins (CP) is another kind of support used in solid-
phase synthesis, consisting of a radiation-grafted polyethylene/polypropylene support.
The number of different supports used in the last two years is vast, however, polystyrene
still provides one of the main workhorse resins today.
The carbodiimides are well-known condensing agents in peptide synthesis.
Various polymers containing the carbodiimide functional group in their backbone have
been known for some time as polymers with film- and fiber-forming capabilities .
PS-Carbodiimde is a neutral, tethered carbodiimide that may be used for the
synthesis of amides, esters, and activated esters. It is a 1% cross-linked poly(styrene-co-
divinylbenzene) resin with a loading capacity of 0.9-1 .4 mmol/g. In comparison with
other carbodiimde resins, PS-Carbodiimide has been found to be highly stable at room
temperature, and has given superior results relative to N-Cyclohexylcarbodiimide-N'-Me
PS resin and the quaternary carbodiimide resin
P-EDC17 The structures of each of these
resins can be seen in Figure 1.3.
Figure 1.3: Structures of Carbodiimide Resins
N=C=NEt
P-EDC
N=C=N
N-Cyclohexylcarbodiimide-V-Me PS
PS-Carbodiimide
PS-Carbodiimide affords amides in high yield and purity without evidence of
residual amine or carboxylic acid impurities. The carboxylic acid, normally used in
excess relative to the amine, remains bound to the resin during work-up17.
1.3.7 Selection of the Protecting Group
The use of selective protection of organic functional groups is a key aspect of
contemporary organic synthesis. Many protective groups have been, and are being,
selectively developed for the purpose ofmultifunctional, temporary protection'8. The
selective protection for the amino group has received considerable attention, specifically
the use of carbamates. Carbamates are ideally suited to protect amino acids in peptide
and protein synthesis due to their ability to minimize base-catalyzed racemization during
synthesis'9.
The most widely used carbamate in organic synthesis is the 9-fluorenylmethyl
carbamate, or Fmoc. Fmoc is a base-labile protecting group with numerous advantages.
Fmoc is readily cleaved in a nonhydrolytic fashion and has excellent acid stability. Other
standard peptide protecting groups, such as t-Boc (tert-butyloxycarbonyl), can also be
removed in its presence. Upon the removal of the Fmoc group in solution, the amine
generated is the desired free base.
Figure 1 .4: Structures of t-Boc and Fmoc Protecting Groups
H O \ l / C OCONHR
H /^\ H2
Although the most widely used protecting group in combinatorial synthesis is
Fmoc, t-Boc is also a very satisfactory labile group that is stable at room temperature (see
Figure 1 .4). The development of Fmoc peptide synthesis arose out of concern that
repetitive TFA acidolysis in Boc-group deprotection could lead to alteration of sensitive
peptide bonds as well as acid catalyzed side reactions . By contrast, Fmoc synthesis
requires only the use of a mild base treatment, while cleavage and deprotection in the Boc
strategy requires the use of dangerous HF and expensive laboratory apparatus.
1 .3.8 Removal of the Fmoc Group in Solution
The Fmoc group is cleaved under mild conditions with an amine base to afford
the free amine and dibenzofulvene. Figure l .5 outlines several amine bases and their
effectiveness in the removal ofFmoc'8. However, incomplete Fmoc removal may occur
during the coarse of the synthesis, leading to poor results. This may be attributed to
unfavorable hydrophobic interactions of the bulky Fmoc moiety. The use ofbase,
particularly piperidine, in the removal of Fmoc may lead to the trapping of the released
12
dibenzofulvene. This problem may result in alkene polymerization and problems in
purification.
Figure 1 .5: Half-Lives for the Deprotection of FMOC by a Variety of Amine
Bases in DMF
Amine tl 2
20% Piperidine 6s
5% Piperidine 20 s
50% Morpholine l min
50% Dicyclohexylamine 35 min
10% p-Dimethylaminopyridine 85 min
50% Diisopropylethylamine 10.1 h
The classical means ofFmoc deprotection employs a large excess of a secondary
amine, such as piperidine, in DMF. The piperidine functions both as a base to fragment
the Fmoc group and as a scavenger to trap the liberated dibenzofulvene (DBF) via a
Michael-type addition thereby outcompeting reaction with the product amine (Scheme
1 Use ofpiperidine/DMF is better suited to Fmoc deprotections on solid-phase than
those in solution due to the low volatility of these solvents, the solvent-dependent
reversible scavenging of dibenzofulvene by piperidine, and DBF polymerization at higher
concentrations
21
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Scheme 1.2: Deprotection of Fmoc by Piperidine
H,N-R
H-.N-R
NHR
1.3.9 Use of PS-Thiophenol in Fmoc Scavenging
An alternative to Fmoc removal requires the use of polymer-supported thiophenol
to scavenge alkylating agents. PS-Thiophenol (3-(3-mercaptophenyl)propan-
amidomethylpolystyrene) is based on an aminomethyl resin with a tethered thiophenol
functionality (Fig. 1.6). PS-Thiophenol was tested and found effective in scavenging
alkylating agents ranging from octyl bromide to benzyl bromide .
In order to cleave disulfide linkages that may be present, the resin is pre-treated
with a 0.7 M tributylphosphine solution for 1 hour, and is then washed with
deoxygenated THF. Effective scavenging of alkyl halides requires the use of the
potassium thiolate salt, formed with potassium trimethylsilanolate.
14
Figure 1.6: PS-Thiophenol
Ermann, et.al., recently described an efficient solution-phase synthesis of
substituted benzimidazol-2-ones in which polymer-supported thiophenol was used to
remove excess alkylating agents22. In previous work, the heterocycle was alkylated using
a variety of alkyl halides. A deprotection step was necessary in order to give the desired
product. However, using the polymer-supported thiophenol, this group was able to
bypass these additional purification and isolation procedures by selective removal of
excess alkylating agents. Derivatives were obtained in high yields and purities.
1.3.10 Analytical Evaluation of Reaction Mixtures
Compared to solution-phase organic synthesis, solid phase reactions are generally
more difficult to monitor principally because the technique of following a reaction by
TLC is not appropiate23. Currently, the methods used for monitoring solid-phase
reactions include analyzing the molecule while it is still bound to the resin, utilizing FT-
IR, l3C gel NMR, and magic angle NMR. It is also possible to remove a small portion of
the resin and cleave the small molecule fragment. This can be accomplished using
MALDI-TOF MS. Matrix-assisted laser desorption/ionization-time of flight mass
spectrometry is a technique in which a co-precipitate of a UV-light absorbing matrix and
a biomolecule are irradiated by a nanosecond laser pulse. Most of the laser energy is
absorbed by the matrix, which prevents unwanted fragmentation of the biomolecule.
15
In comparison, the primary advantage of solution-phase chemistry is its
familiarity to the synthetic chemist. Reactions are generally amenable to easy tracking
and analysis24. This closely parallels general experience in the pre-combichem days with
the exception that the workload is greatly magnified. Automation is called for, and LC/
mass spectrometry is of particular value25. It is also possible to monitor the reaction
progress through TLC and analytical HPLC.
However, with very large libraries, analytical evaluation is usually restricted by
necessity to statistical sampling and compound identification rarely goes beyond
ascertaining whether the product has the correct molecular weight. If activity is found
then more detailed examination takes place.
1.3.11 Informetrics
The generation of large libraries combined with robotic screening processes
produce an enormous amount of data. Keeping track of these libraries is a job for high
speed computers. Many firms have developed their own programs for the data handling,
and there are commercial packages that may be useful as welf
1.4 COMBINATORIAL SYNTHESIS: PEPTIDOMIMETICS
The discovery of the physiological role of a great number of peptides stimulated
researchers all over the world towards design and synthesis of peptidomimetics, or
peptide-like molecules. Natural peptides can seldom be used therapeutically as drugs,
because of the problems associated with low absorption, rapid metabolism, and low oral
bioavailability, therefore many efforts have been aimed at modifying the natural sequence
of the amino acids. This creation of entirely artificial substances for use as medicinal
16
agents is attributed to an interest in the elucidation of reactions found in biosynthetic and
metabolic pathways26.
Synthetic, non-natural peptides have the advantage ofproviding new
functionalities that can circumvent natural processes in the body. For example, they
become able to perform functions that are not available with the natural materials, such as
binding to and penetrating cell membranes and resisting degradation by enzymes.
In solid-supported combinatorial synthesis, many of the linkers that are available
require polar functional groups for binding, and the same polar groups are released after
cleavage. To generate libraries with biological activity, however, such polar
functionalities may possess unfavorable pharmacological properties. The synthesis of
peptidomimetic libraries has become an appealing target in response to the poor oral
bioavailability and enzymatic degradation of linear peptides27.
Due to the nonpolar nature and steric bulkiness of its side chain, phenylalanine is
one of the preferred residues in peptidomimetics when the biological targets are known to
have hydrophobic binding sites. In order to increase the bioavailbility of compounds
derived from peptidomimetic approaches, amino acid residues with bulky and
hydrophobic side chains are often left unchanged where other residues are modified. In
this regard, phenylalanine is considered to be a key pharmacophore in many biologically
important peptide-like molecules.
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2 OBJECTIVE
The production of peptidomimetics, or peptide-like molecules, is a valuable tool
in the pharmeuceutical industry. Natural peptides can seldom be used therapeutically as
drugs due to problems associated with poor absorption, rapid metabolism, and low oral
bioavailability. Recent efforts have been made to synthesize bioactive peptides that are
recognized by a peptide recognition site28Therefore, by mimicking important structural
features of peptides, one may simultaneously maintain beneficial biological activities29.
One class of synthetic non-natural peptides attaches small peptide sequences to
organic molecules. This has the advantage of providing new functionalities that can
circumvent natural processes in the body. Combinatorial techniques, both solution-phase
and solid-phase, have allowed for the rapid production of these molecules. These
techniques, combined with robotic screening, have greatly accelerated drug
discovery"
The goal of this research is to synthesize a solution-phase library of PABA-based
peptide analogs using a solid supported reagent. Using ethyl p-aminobenzoate as the
backbone for our synthesis, it was our aim to produce a small library of tri-peptide
analogs through the parallel addition of three different amino acids to this template. A
secondary goal in this project was to determine the fastest route in the FMOC
deprotection of these analogs, using either piperidine or a polymer-supported thiophenol.
Scheme 2.1 illustrates an overview of our solution-phase peptide synthesis and
deprotection sequence.
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Scheme 2.1: Solution-Phase Peptide Synthesis
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2.1 SYNTHESIS OF MONO-PEPTIDE ANALOGS
Two procedures for the production of the initial analogs were evaluated. The
procedure that afforded the highest yield ofprotected product was used for the remaining
syntheses of di- and tri-peptide analogs. A total of 27 tri-peptide analogs were produced,
which included derivatives of phenylalanine, valine, and isoleucine.
2.2 DEPROTECTION OF PEPTIDE ANALOGS
Two different means of deprotection were evaluated: piperidine in DMF and PS-
Thiophenol. The deprotection agent that afforded the highest yield of free amine was
used to deprotect the final 27 tri-peptide analogs. The separation of the protecting group
by-product from the reaction mixture was also a factor in choosing the ultimate agent.
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3 EXPERIMENTAL
Reagents and solvents were obtained from the Sigma-Aldrich Chemical Co. All
solvents were A.C.S. HPLC Grade. Polymer supported resins, including PS-
Carbodiimide and PS-Thiophenol, were obtained through Argonaut Technologies Inc.
All reactions were carried out in BIO-RAD Econo-Pac Columns. These
polypropylene columns were 14 cm high with dimensions of 1.5 x 12 cm. Allowing for
easy filtration, each vial contains a porous 30 (um) polyethylene bed support.
3.1 SYNTHESIS OF MONO-PEPTIDE ANALOGS
Three mono-peptide analogs were produced by linking ethyl para-aminobenzoate,
or PABA, to each of the following amino acids: N-(9-Fluorenylmethoxycarbonyl)-L-
phenylalanine, N-(9-Fluorenylmethoxycarbonyl)-L-valine, and N-(9-
Fluorenylmethoxycarbonyl)-L-isoleucine. PS-Carbodiimide resin, or DCC, was used as
the support bound reagent.
3.1.1 Procedure A
Fmoc-phenylalanine (1.2g, 3.0 mmol, 1.5 equiv) and PABA (.33g, 2.0 mmol, 1
equiv) were combined and allowed to react for 10 minutes in CH2C12:DMF (1:1,
lOml/gram of resin). PS-Carbodiimide (1.5g, 2.0 mmol, 1 equiv) was then added and the
complete mixture was allowed to turn end over end for 24 hours .
Fmoc-valine (l.Og, 3.0 mmol, 1.5 equiv) and Fmoc-isoleucine (l.lg, 3.0 mmol,
1 .5 equiv) were treated in the above fashion in order to yield the remaining of the two
mono-peptide analogs.
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3.1.2 Procedure B
PS-Carbodiimide (2.3g, 3.0 mmol, 1.5 equiv) and Fmoc-phenylalanine ( 1 .2g, 3.0
mmol, 1.5 equiv) were combined and allowed to react for 10 minutes in CH2C12:DMF
(1:1, lOml/gram of resin). PABA (.33g, 2.0 mmol, 1 equiv) was then added and the
complete mixture was allowed to turn end over end for 24 hours.
Fmoc-valine (l.Og, 3.0 mmol, 1.5 equiv) and Fmoc-isoleucine (l.lg, 3.0 mmol,
1 .5 equiv) were also treated in the above fashion in order to yield the remaining of the
two mono-peptide analogs.
3.1.3 Reaction Workup
Following each procedure, the resin was removed by filtration and washed two
times with CH2Cl2:DMF (1:1, 3ml). The filtrate was then transferred to a clean reaction
vessel where the deprotection reaction occurred.
3.1.4 Deprotection of the FMOC Protecting Group
Following procedure A, piperidine in DMF (1:1, 5ml) was added to each reaction
vessel. The reaction was allowed to turn end over end for two hours.
Following procedure B, piperidine in DMF ( 1 : 1, 2.5 ml) was added to each
reaction vessel. The reaction was allowed to turn end over end for two hours.
3.1.5 Isolation of the Free Amine
In order to isolate the product, HPLC grade water (2 ml) was added to the solution
prepared from procedure A. The precipitated product was dried in a dessicator for 1 hour
and stored for analytical evaluation. Water was removed from the remaining solution as
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an azeotrope using an equivalent amount of ethanol. The mixture was then stored in the
freezer for analytical evaluation.
Following procedure B, the entire mixture was stored in the freezer. Upon the
precipitation of product, the solution was filtered and the crystals were collected by
vacuum filtration. Both the remaining solution and precipitated material were stored in
the freezer for further evaluation.
3.2 SYNTHESIS OF DI-PEPTIDE ANALOGS
The second phase of this library was synthesized by parallel addition of each of
the three mono-peptide analogs to each of the three chosen amino acids. A total of 9 di-
peptide analogs were produced.
3.2.1 Procedure
To a total of 9 filter reaction vessels, PS-Carbodiimide (2.3g, 3.0 mmol, 1.5
equiv) was added in CH2C12:DMF (1:1, lOml/gram of resin). Fmoc-phenylalanine (1.2g,
3.0 mmol, 1.5 equiv), Fmoc-valine (l.Og, 3.0 mmol, 1.5 equiv), and Fmoc-isoleucine
( 1 . lg, 3.0 mmol, 1 .5 equiv) were then added three fold and allowed to turn end over end
for 10 minutes.
Each of the three mono-peptide analogs was added in parallel to the protected
amides. The deprotected phenylalanine analog (0.2 lg, 2.0 mmol, 1 equiv), the valine
analog (0.1 8g, 2.0 mmol, 1 equiv) and the isoleucine analog (0.28g, 2.0 mmol, 1 equiv)
were added to the reaction mixture and the reaction was allowed to turn end over end for
24 hours.
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3.2.2 Reaction Workup
The reaction mixture was filtered into a clean reaction vessel and the protected di-
amide product was collected in the filtrate. The resin was then further washed an
additional two times with CH2C12:DMF(1:1, 3 ml).
3.2.3 Deprotection of the Fmoc Protecting Group
Piperidine in DMF (1:1, 3ml) was added and allowed to react for two hours.
After freezing, the solid precipitate was collected by vacuum filtration. The filtrate was
stored in the freezer for further evaluation.
3.3 SYNTHESIS OF TRI-PEPTIDE ANALOGS
The third phase of this library was synthesized by parallel addition of the nine
deprotected peptide analogs to each of the three chosen amino acids. A total of 27 tri-
peptide analogs were produced.
3.3.1 Procedure
To a total of 27 filter reaction vessels, PS-Carbodiimide ( 1 .4g, 2.0 mmol, 1 .5
equiv) was added in CH2C12:DMF (1:1, lOml/gram of resin). Fmoc-phenylalanine
(0.77g, 2.0 mmol, 1.5 equiv), Fmoc-valine (0.68g, 2.0 mmol, 1.5 equiv), and Fmoc-
isoleucine (0.7 lg, 2.0 mmol, 1.5 equiv) were then added nine fold and allowed to turn
end over end for 10 minutes.
Each of the nine di-peptide analogs was added in parallel to the protected amino
acids. The molar amounts and equivalents of each can be seen in Table 3.1.
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Table 3.1: The Parallel Addition of Nine Di-Peptide Analogs
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O O
H || H
HNCCN-CCNH,
I H I
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g/mol
0.56g
1.3 mmol
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I H I
CH2 CH
/ \
H3C CH3
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g/mol
0.54g
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II H || H
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CH2 HCCH2CH:
CH,
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0.55g
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g/mol
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H II H
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CH CH
/ \ / \
H3C CH3 H3C CH3
363.46
g/mol
0.47g
1.3 mmol
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CO,CH,CH,
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I H I
CH CH-CH,CH-
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H3C CH3 H,C
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g/mol
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.3 mmol
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I H \
HC-CH2CH3 CH2
CH3
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g/mol
0.55g
1.3 mmol
1 equiv
C02CH2CH3
O O
H II H
HNCCNCCNH2
I H \
HC-CH2CH3 CH
I ' \
CH, H3C CH:
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g/mol
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o o
II H || H
-CCNCCNH,
I H V
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CH3 CH3
391.5
g/mol
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1.3 mmol
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*Per 1 equivalent of amino acid. Quantitative yields of di-peptide analogs are assumed
as they are added in parallel to each of the three amino acids.
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3.3.2 Reaction Workup
The reaction mixture was filtered into a clean reaction vessel and the protected tri-
amide product was collected in the filtrate. The resin was then further washed an
additional two times with CH2C12:DMF(1:1, 3 ml).
3.3.3 Deprotection of the Fmoc Protecting Group
PS-Thiophenol (1.3g, 2.0 mmol, 1 equiv) was treated with 20 ml of potassium
trimethylsilanolate (5 1 3 mg, 4.0 mmol, 2 equiv) in THF:EtOH (1:1) and allowed to turn
end over end for 30 minutes. The solution was removed by filtration and the resin was
washed three times with THF:EtOH (1:1).
Three of the 27 tri-peptide reaction mixtures were added to this prepared bed of
PS-Thiophenol and allowed to turn end over end for 24 hours. The reaction was filtered
and the deprotected product was collected in the filtrate.
The remaining of the tri-peptides were deprotected in the same fashion as reported
for each di-peptide analog.
26
3.4 ANALYTICAL EVALUATION OF MONO-PEPTIDE ANALOGS
3.4.1 Evaluation of Solid Precipitate
The white precipitates obtained from both procedures A and B were analyzed by
melting point and NMR, using a Bruker 300MHz instrument. Proton NMR analysis was
performed by dissolving 5 mg of sample in D-chloroform, with the addition of 2 drops of
TMS.
3.4.2 LC-MS Evaluation of Reaction Mixture
A Hewlett Packard 1 100 HPLC equipped with a diode array detector and
quadrapole mass spectrometer was employed to gain quantitative and qualitative analyses
of each reaction mixture.
Sample Concentration: ~lmg/ml in CH2Cl2/5% TFA.
Column: Hypersil BDS-C18 5u. (3 x 50 mm).
Injection Volume: 1 ul.
Solvent A: 0.1 M Ammonium Acetate Buffer, pH 4.65.
Solvent B: Acetonitrile:Isopropanol (1:1).
Gradient: 90% A/10% B (equilabrate for 4 minutes) to 100% B (10 minutes);
hold(l min).
Flow Rate: 2.0 ml/min
Detection: Quadrapole Mass Spectrometer, scanned from 65 to 2000 amu,
alternating + and
- ions.
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3.5 ANALYTICAL EVALUATION OF Dl- AND TRI-PEPTIDE ANALOGS
All remaining precipitates were analyzed by melting point only. A Hewlett
Packard (Agilent) 1 100 HPLC equipped with a diode array detector and quadrapole mass
spectrometer was employed to gain quantitative and qualitative analyses of each reaction
mixture.
Sample Concentration: ~lmg/ml in CH2Cl2/5% TFA.
Column: Zorbax 18 (2.1 x 150 mm)
Injection Volume: 2 ul
Solvent A: 0.1 M Ammonium Acetate Buffer, pH 4.65.
Solvent B: Acetonitrile:Isopropanol (1:1).
Gradient: 80% B-100% B in 10 minutes; hold (4 min)
Flow Rate: 0.4 ml/min
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4 RESULTS
4.1 ANALYSIS OF MONO-PEPTIDE ANALOGS: PROCEDURE A
Figure 4.1 shows the chromatogram of the reaction mixture following procedure
A. The heating of the reaction mixture has lead to a reversal in the reaction, accounting
for the large presence of PABA and amino acid starting materials.
Figure 4.1: Chromatogram of Deprotected Mono-Peptide Analog
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4.2 ANALYSIS OF MONO-PEPTIDE ANALOGS: PROCEDURE B
Figures 4.2-4.4 show the LC-MS for each of the three mono-peptide analogs.
With the absence of any PABA starting material, mono-peptide analogs were synthesized
with yields greater than 90%.
Figure 4.2: LC-MS Chromatogram of Phenylalanine Analog (1A)
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Figure 4.3: LC-MS Chromatogram of Valine Analog (2A)
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Figure 4.4: LC-MS Chromatogram of Isoleucine Analog (3A)
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Table 4.1 : Summary of Library Results of Mono-Peptide Analogs
Product %PABA %Product %Othe r Impurities
1A 0 96 4.2
2A 0 94 6.5
3A 0 97 3.4
*A11 HPLC analysis has been carried out under the assumption that all molar responses
are equal.
Table 4.2: Numbering System for Amino Acids
1A Phenylalanine
_sK )
2A Valine ,CH3
CH
^CH3
3A Isoleucine r
C CH3
H
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4.3 ANALYSIS OF FMOC BYPRODUCT
Figure 4.5: NMR Spectra of Precipitated Fmoc
Fmoc analysis was accomplished using NMR, as seen in Figure 4.5. Melting
point analysis can be found in Tables 4.3-4.4.
... .*.., . ...,./,> Jv v w-A -4L nU'"i jyuUJv
Table 4.3: Melting Point Results- Precipitated FMOC from Mono-Peptide
Analogs
Fmoc Precipitate Melting Point (C)
la
2a
3a
104-106
94-96
98-101
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4.4 INITIAL ANALYSIS OF DI-PEPTIDE ANALOGS
Table 4.4: Melting Point Results- Precipitated DBF From Mono-Peptide
Analogs
Fmoc Precipitate Melting Point (C)
la-la 239-241
la-2a 240-242
la-3a 240-241
2a- la 236-238
2a-2a 248-250
2a-3a 242-244
3a- la 247-249
3a-2a 248-250
3a-3a 249-251
Figure 4.6: LC-MS Chromatogram of Deprotected Di-Peptide Analog
Column: Hypersil BDS-C18
Initial analytical evalution of the di-peptide analogs was performed using a
Hypersil BDS C- 1 8 column. However, unfavorable separation conditions lead us to
examine other means of evaluation. This initial chromatogram is seen in Figure 4.6.
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4.5 OVERALL ANALYSIS OF DI-PEPTIDE ANALOGS
Figure 4.7 shows a general chromatogram for the intermediate di-peptide analogs.
It is important to note that the presence of the PABA starting material surfaces in this
data. The corresponding mass spectrum can be seen in Figure 4.8. The remaining mass
spectrum for the di-peptide analogs are shown in Figures 4.9-4.16. Corresponding
chromatograms can be seen in Appendix B.
Figure 4.7: Chromatogram of Di-Peptide Analogs
Column: ZORBAXC18
Figure 4.8: Corresponding Mass Spectra: Phenylalanine-Plenylalanine
(1A-1A) *Labeled with corresponding retention times.
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Figure 4.9: Mass Spectra: Phenylalanine-Valine (1A-2A)
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Figure 4.10: Mass Spectra: Phenylalanine-lsoleucine (1A-3A)
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Figure 4.11: Mass Spectra: Valine-Phenylalanine (2A-1A)
Figure 4.12: Mass Spectra: Valine-Valine (2A-2A)
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Figure 4.13: Mass Spectra: Valine-lsoleucine (2A-3A)
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Figure 4.14: Mass Spectra: Isoleucine-Phenylalanine (3A-1A)
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Figure 4.15: Mass Spectra: Isoleucine-Valine (3A-2A)
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Figure 4.16: Mass Spectra: Isoleucine-lsoleucine (3A-3A)
100
, ~Q0
I
| "60""]
>
i To~1
cr: Monn-peptnje ;tan ing material, 4 547
3o 273 1
80 160 240 320 400 480 560 640 720 800 830 960 1 040 1120 1200 1280 I 360 1 440 1520 1 600 1680 1760 1840 1920 2000
m/z
3A-3A,6 21 7
100 :
390 ]
e
1
1
:
1 "40~1
"20 ;
[
80 160
|||II|IM
240 320 400 480 560 640 720 300 880 960 1040 1120 1200 1230 1 360 I 440 1520 1 600 1680 1760
m/z
41
Table 4.5: Summary of Library Results of Di-Peptide Analogs
Product %PABA %Mono-peptide %Product %Other Impurities
1A-1A 14.46 7 75 3.05
1A-2A 0 0 96 4.02
1A-3A 0 8.39 91 1.06
2A-1A 20.28 0 78 2.03
2A-2A 0 5.94 93 1.05
2A-3A 0 4.92 94 1.57
3A-1A 14.12 0 83 3.24
3A-2A 0 10.9 87 10.9
3A-3A 0 11.54 87 1.65
42
Figure 4.17: LC of Tri-Peptide Analog: PS-Thiophenol Deprotection
Figure 4.17 shows a chromatogram for a tri-peptide analog deprotected using the
PS-Thiophenol method. The corresponding mass spectrums are seen in Figure 4.18.
Figures 4.19-4.20 show the mass spectrum for the remaining two tri-peptide analogs that
underwent PS-Thiophenol deprotection. Remaining chromatograms can be found in
Appendix C.
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Figure 4.18: Corresponding Mass Spectra (3A-1A-1A)
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Figure 4.19: PS-Thiophenol Deprotection: Mass Spectra (3A-1A-2A)
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Figure 4.20: PS-Thiophenol Deprotection: Mass Spectra (3A-1A-3A)
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Figure 4.21: Chromatogram of Deprotected Tri-Peptide Analog (1A-1A-1A)
Figure 4.21 shoes a general chromatogram for a deprotected tri-peptide analog
obtained by using traditional piperidine deprotection. It is important to note the large
amount ofPABA starting material that is present. Figure 4.22 also shows a deprotected
tri-peptide analog, however, there is no PABA present in this reaction mixture. Figures
4.23-4.45 show the corresponding mass spectrum. Remaining chromatograms can be
found in Appendix C.
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Figure 4.22: Chromatogram of Deprotected Tri-Peptdie Analog (1A-3A-1 A)
*No PABA Cleavage Present
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Figure 4.23: Corresponding Mass Spectra (1A-1A-1A)
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Figure 4.24: Mass Spectra (1A-1A-2A)
Figure 4.25: Mass Spectra (1A-2A-1A)
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Figure 4.26: Mass Spectra (1A-2A-2A)
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Figure 4.27: Mass Spectra (1A-2A-3A)
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Figure 4.28: Mass Spectra (1A-3A-1A)
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Figure 4.29: Mass Spectra (1A-3A-2A)
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Figure 4.30: Mass Spectra (1A-3A-3A)
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Figure 4.31: Mass Spectra (2A-1A-1A)
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Figure 4.32: Mass Spectra (2A-1A-2A)
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Figure 4.33: Mass Spectra (2A-1A-3A)
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Figure 4.34: Mass Spectra (2A-2A-1A)
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Figure 4.35: Mass Spectra (2A-2A-2A)
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Figure 4.36: Mass Spectra (2A-2A-3A)
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Figure 4.37: Mass Spectra (2A-3A-1A)
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Figure 4.38: Mass Spectra (2A-3A-2A)
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Figure 4.39: Mass Spectra (2A-3A-3A)
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Figure 4.40: Mass Spectra (3A-2A-1A)
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Figure 4.41: Mass Spectra (3A-2A-2A)
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Figure 4.42: Mass Spectra (3A-2A-3A)
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Figure 4.43: Mass Spectra (3A-3A-1A)
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Figure 4.44: Mass Spectra (3A-3A-2A)
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Figure 4.45: Mass Spectra (3A-3A-3A)
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Table 4.6: Summary of Library Results of Tri-Peptide Analogs
Product %PABA %Mono-peptide % Di-Peptide %Product %Other Impurities
1A-1A-1A 57.72 13.09 0 27 2.07
1A-1A-2A 0 0 0 86 14.36
1A-1A-3A 36.42 8.39 0 54 1.09
1A-2A-1A 58.25 11.75 0 27 3.45
1A-2A-2A 0 0 18.45 74 7.3
1A-2A-3A 0 0 15.96 74 10
1A-3A-1A 0 0 0 89 10.72
1A-3A-2A 0 0 0 16 84.28
1A-3A-3A 0 0 0 17 83.2
2A-1A-1A 74.35 0 0 17 8.95
2A-1A-2A 0 0 32.42 63 4.53
2A-1A-3A 0 0 0 54 45.75
2A-2A-1A 52.16 20.52 0 20 6.58
2A-2A-2A 0 0 27.99 65 6.94
2A-2A-3A 0 0 0 70 30.16
2A-3A-1A 70.31 0 0 21 8.95
2A-3A-2A 0 0 0 83 17.25
2A-3A-3A 0 0 0 66 33.51
3A-1A-1A 5.98 0 0 7 87.2*
3A-1A-2A 0 13.54 0 8
77.67*
3A-1A-3A 0 0 0 6
93.73*
3A-2A-1A 72.84 0 0 20 6.95
3A-2A-2A 0 0 34.06 62 3.67
3A-2A-3A 0 0 0 62 37.41
3A-3A-1A 74.13 0 0 14 11.27
3A-3A-2A 0 0 0 57 43.06
3A-3A-3A 0 0 30.56 60 9.24
PS-Thiophenol Deprotection.
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5 DISCUSSION
5.1 SYNTHESIS OF MONO-PEPTIDE ANALOGS
The synthesis of the three amino acid-bound analogs was first carried out using a
procedure (A) from Argonaut Technologies'7. Procedure A required the use of only l
equivalent of the resin per 1.5 equivalents of the protected amino acid. The ethyl p-
aminobenzoate and the amino acid in CH2C12:DMF were combined in a fritted
polypropylene reaction vessel and allowed to react for 10 minutes. Upon the addition of
PS-Carbodiimide, the reaction mixture was turned end over end at room temperature. It
is important to note that the polymer-supported DCC is added after both the p-
aminobenzoate ester and the amino acid. After a reaction time of 24 hours, piperidine
was added to deprotect the Fmoc group followed by the addition ofwater to precipitate
the Fmoc byproduct from solution. The white precipitates from each of the three reaction
mixtures were analyzed and found to be 9-fluorenemethanol. Structure verification can
be seen in Figure 4.5. The melting point determination of each of these solids was found
to be comparable with the literature melting point of 102-104C for 9-fluorenemethanol
(Table 4.1).
Following Fmoc precipitation, it was necessary to remove the water by formation
of an azeotrope from each solution by adding an equivalent amount of ethanol followed
by attempted removal of the solvent in vacuo. However, the LC of this reaction mixture
shows a reversal of the reaction due to the need to heat the solution during the attempted
evaporation (Figure 4.1). Although product is visible, there is a considerable amount of
amino acid and ethyl p-aminobenzoate starting materials, which were not present prior to
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the addition of the aminoester. Thus another method, other than the addition ofwater,
was needed to remove the Fmoc byproduct from solution.
We also believed that the order of addition of reactants played a key role in the
outcome of this reaction. Procedure A was modified to Procedure B, where equivalent
amounts of carbodiimide and protected acid were allowed to react prior to the addition of
the template. Our goal here was to ensure that the carbodiimide would properly activate
the amino acid, prior to the addition of the template. Using this modified procedure, the
reaction mixtures were then placed in the freezer where the 9-fluorenemethanol
precipitated from solution over a short period of time. The LC-MS of each of the three
mono-peptides synthesized using Procedure B can be seen in Figures 4.2.-4.4. The
deprotected peptide analogs were synthesized with yields >90%. It was then decided to
add each additional amino acid to the template using our revised Procedure B.
5.1.1 Analytical Evaluation ofMono-Peptide Analogs
LC-MS ofproteins and peptides is used to provide information for protein
characterization, to accurately identify post-trans lational modifications ofproteins, and to
determine the molecular weight of synthetic and naturalpeptides". The characterization
of the reaction mixtures for each of the mono-peptide analogs was performed using a
Hypersil BDS-C18 column. This column was chosen due to the fact that it is base
deactivated and endcapped to improve peak shapes ofbasic solutes by minimizing
interaction with unreacted silanols. Literature references to use of the Hypersil BDS
column include detection ofbasic drugs, explosives, and antibiotics.
In order to detect the molecular weights present in each reaction mixture, a
quadrapole mass spectrometer was utilized and scanned from 65 to 2000 amu, alternating
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positive and negative ions. The deprotected peptide analog was detected only in negative
ion mode, resulting in a clean spectra and positive structure identification.
5.2 SYNTHESIS OF DI-PEPTIDE ANALOGS
The synthesis of the nine di-peptide analogs was carried out using our revised
Procedure B. This second phase of the library was produced by parallel addition of each
of the three mono-peptide analogs to each of the three chosen amino acids. Table 5.1
illustrates this intermediate library of nine di-peptide analogs.
5.2.1 Analytical Evaluation of Di-Peptide Analogs
Upon the addition ofpiperidine to deprotect the Fmoc group from solution, the
reaction mixture was again frozen. Over a short period of time, a white precipitate began
to form. However, upon melting point analysis, it was revealed that this was not 9-
fluorenemethanol, as we had previously seen with the mono-peptide analogs. The
melting points of each precipitate can be seen in Table 4.2. It was possible that our
deprotected product had precipitated out of solution, and that selective recrystallization
had occurred. However, LC-MS characterization revealed that this white solid was
actually liberated dibenzofulvene (DBF), as a result of the addition of piperidine.
Piperidine functions as both as base to fragment the Fmoc group and as a scavenger to
trap the liberated DBF via a Michael-type addition thereby outcompeting reaction with
the product amine. This is schematically illustrated in Scheme 1.2.
With the characterization of the DBF complete, our attention then shifted to the
analysis of the reaction mixture, where our deprotected product should have then
remained in solution. Initially, the same method was employed to characterize these di-
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peptide analogs as was used with the mono-peptide analogs. However, separation of the
remaining impurities and starting materials from the desired product could not be
accomplished using a Hypersil BDS-C18 column (Figure 4.6). These remaining
components in solution did not allow the deprotected product to properly ionize, thus
positive structure identification for the desired product could not be acheived.
After the first attempt to characterize the di-peptide analogs failed, we then turned
to an Agilent ZORBAX reversed phase CI 8 column. This column is based on Rx-SIL,
and is aimed at providing the best peak shape and sample resolution, as well as the
longest lifetimes for the low, mid, and high pH regions. Specifically, the C18 column is
an efficient, silica-based column, designed for the separation ofbasic analytes, including
peptides.
A sample chromatogram using the ZORBAX column is illustrated in Figure 4.7.
Positive structure identification was achieved for all nine of the di-peptide analogs. The
mass spectra for each analog can then be seen in Figures 4.8-4. 1 6. Several mass spectra
also indicate that the di-peptide reactions did not go to completion, indicated by the mass
of the mono-peptide starting material. PABA is also present in several of the spectra,
possibly indicating the cleavage of the PABA from the terminal peptide chain. The
formation of deprotected product in solution allowed for the addition of one more amino
acid to the template.
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Table 5.1 : Library of Intermediate Di-Peptide Analogs
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5.3 SYNTHESIS OF TRI-PEPTIDE ANALOGS
The synthesis of the 27 tri-peptide analogs was also carried out using our revised
procedure B. This third, and final, phase of the library was produced by parallel addition
of each of the nine di-peptide analogs to each of the three chosen amino acids. Table 5.2
illustrates the complete library of tri-peptide analogs.
Table 5.2: Library of Tri-Peptide Analogs
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5.4 DEPROTECTION OF THE FMOC GROUP
5.4.1 Use of a Polymer-Supported Thiophenol as a Scavenger
It was our goal to rapidly produce a library via parallel synthesis techniques,
however, the length of time required to fully precipitate DBF from solution has been the
limiting factor in the production of this library. Upon the synthesis of the final 27
analogs, PS-Thiophenol was chosen as a scavenger and added to three of the analogs. It
was believed that this thiol-based Michael donor might replace piperidine as a superior
DBF scavenger capable of outcompeting the product amine nucleophile.
In order for effective scavenging to occur, the use of the potassium thiolate salt is
required. This salt was formed with the addition of potassium trimethylsilanolate in
THF:EtOH to the bed of PS-Thiophenol. The solution was then turned end over end in a
filter reaction vessel for 30 minutes. The solution was removed by filtration and the resin
was washed three times with THF:EtOH. The three analogs were added to separate beds
of the prepared PS-Thiophenol and allowed to turn end over end at room temperature.
After a reaction time of 24 hours, the reaction was filtered and the product was collected
in the filtrate.
LC-MS evaluation of the three analogs only revealed a 6-8% yield of deprotected
product. Figure 4. 1 7 shows the chromatogram for one of these analogs deprotected under
scavenging conditions. In all three cases, the majority of the reaction mixture was the
protected tri-peptide analog. Figures 4. 1 8-4.20 are the corresponding mass spectra for
each of the three analogs. As a precautionary measure, Argonaut Technologies suggests
that PS-Thiophenol should first be prepared for use by reduction with a tributylphosphine
solution in order to cleave disulfide linkages that may be present This preparation was
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not attempted in our studies due to the expense of the reducing reagent. The use of PS-
Thiophenol as a method to cleave Fmoc from the desired product might have been more
successful had we done the suggested preparatory reaction. The production of a very
small yield of deprotected product concluded that the use ofpiperidine to deprotect the
Fmoc group was a better method than that of PS-Thiophenol scavenging.
The remaining 24 analogs were then deprotected in the same fashion as were the
mono- and di- peptide analogs. Figures 4.21 and 4.22 illustrate general chromatograms
for the tri-peptide analogs. In figure 4.21, PABA is present in significant amounts, where
in Figure 4.22, PABA can not be seen. The corresponding mass spectra can be seen in
Figures 4.23-4.45. The positive structure identification occurred for all 24 remaining
analogs. In several of the spectra, the original template, PABA, can be seen. Again, the
cleavage ofPABA may be occurring, contributing to lower yields of deprotected product.
In several instances, remaining mono-peptide starting material can be seen, as well as di-
peptide material, indicating an incomplete reaction.
5.5 COMPARISON OF LIBRARY RESULTS
The evaluation of the initial three mono-peptide analogs showed almost
exclusively the expected deprotected product, with very few impurities present. The
most important thing to note is that the original template, PABA, could not be seen in the
mass spectra at this time. Also the addition of piperidine to deprotect the terminal amino
acid resulted in isolation of 9-fluorenemethanol whose structure was confirmed by
melting point and NMR.
The appearance ofPABA in the LC spectra begins with the evaluation of the di-
peptide analogs, and continues with the tri-peptide analogs. This appearance is both
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sequential and exponential in the di- and tri-peptide analogs. It is believed that with the
buildup ofpiperidine in solution, comes the cleavage of the original template, PABA,
from the terminal peptide link. PABA, being an aromatic amine, is the weakest base and
therefore the most likely piece to be cleaved from the remaining peptide upon the
addition of piperidine. In addition, initial evaluation of the mono-peptide analogs
concluded that the reaction does reverse upon heating. This brings us to a reliable
conclusion that the PABA amide is the weakest link in the molecules.
The amount of PABA present in the tri-peptide reaction mixture results in a much
lower yield for some members of that library. The huge excess ofpiperidine, which has
been building up after each deprotection step, results in significant cleavage of the
original PABA template. As more piperidine is present in the solution, more PABA is
observed in the product mixture.
It is also interesting to note that with the first mono-peptide reaction, 9-
fluorenemethanol was produced as a by-product of piperidine deprotection. However,
with both the di- and tri-peptide analogs, dibenzofulvene was released as a by-product.
This may also result from the increasing and building concentration ofpiperidine in the
solution.
70
6 CONCLUSION
It was Merrifield who stated in 1969 with regard to solid-phase organic chemistry:
"A gold mine awaits discovery by organic chemists31."As a result ofMerrifield's work,
combinatorial synthesis of libraries containing small organic molecules has become a
rapidly evolving area of research. Both solid-phase and solution-phase strategies have
been utilized to generate whole libraries of structurally related compounds.
Our current research successfully resulted in the synthesis of a solution-phase
library ofPABA-based analogs using a solid supported reagent. Using ethyl p-
aminobenzoate as the backbone for our synthesis, we were able to produce a library of 27
tri-peptide analogs through the parallel addition of three different amino acids to this
template.
Mono-peptide analogs were synthesized in solution with yields >90%. As
predicted, with the addition of each amino acid to the template, the percentage ofpurity
decreased. Di-peptide analogs were synthesized with 75-95% purity, while tri-peptide
analogs gave an average yield of45%. These yields varying from 14-54% show
significant cleavage of the PABA template in some cases. It was also found that the use
of a mild base, piperidine, was the fastest route to the Fmoc deprotection of these
molecules, compared to the use of a polymer-supported thiophenol. However, the release
of the by-product, dibenzofulvene, during Fmoc deprotection leads to some difficulty
with respect to isolation and characterization of the desired product. It was also observed
that with the buildup ofpiperidine in solution, the original template, PABA, began to
cleave from the terminal peptide link. This significant cleavage resulted in lower yields
of the tri-peptide analogs.
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It is safe to conclude that the coupling reaction to form tri-peptide analogs worked
extremely well. However, the deprotection of these analogs still needs to be optimized.
The primary goal of this research was to develop a synthetic method for rapid production
of a diverse set of tri-peptide analogs, with less concern for the production of compounds
of high purity. This goal was achieved and these procedures can be used to synthesize
analogs containing longer peptide chains, ifnecessary.
6.1 FUTURE WORK
In order to preserve the deprotected peptides, future work must be done in order
to base scavenge the excess piperidine prior to each parallel addition. Base scavenging
may lead to higher yields, eliminating significant cleavage resulting in the excess buildup
of piperidine. One reagent that may be used is PS-Isocyanate, which is produced by
Argonaut Technologies. This resin may be used in order to scavenge excess nucleophiles
from solution, and occurs without liberation of small molecule byproducts17. Once
scavenged, the piperidine will be removed from the reaction mixture, allowing for the
subsequent addition of amino acids to occur. In addition, further research into PS-
Thiophenol scavenging may also result in less cleavage ofPABA as the peptide chain is
increased.
Upon the successful production of a library of tri-peptide analogs, some future
applications for these compounds may exist. An efficient method for the solid-phase
synthesis of individual bis-cyclic thioureas from resin bound tri-peptides has previously
been Substituted thioureas possess a wide variety ofknown biological
activities, including antioxidant active compounds with potent anti-HIV activity.
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Following this procedure, it may be possible to reduce PABA-bound tri-peptides in
solution in order to achieve similar results (Scheme 6. 1 ).
Scheme 6.1: Synthesis of Bis-2-lmidazolidinethiones
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APPENDIX A MONO-PEPTIDE ANALOGS
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A3: LC-MS Isoleucine Analog (3A)
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APPENDIX B DI-PEPTIDE ANALOGS
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APPENDIX C TRI-PEPTIDE ANALOGS
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